Benign Prostatic Hyperplasia Treatment Market is predicted to reach USD 18.1 Billion at a CAGR of 5.50% during the forecast period 2032

Market Research Future (MRFR) has published on the “Global Benign Prostatic Hyperplasia Treatment Market”

Benign Prostatic Hyperplasia Treatment Market Highlights

The global benign prostatic hyperplasia treatment market is accounted to register a CAGR of 5.50% during the forecast period and is estimated to reach USD 18.1 Billion by 2032.

The market for medicines and procedures for people with an enlarged prostate (benign prostatic hyperplasia, or BPH) is a booming industry. It includes prescription medications, minimally invasive techniques, and surgical choices. The prevalence of BPH is rising, and treatment options are improving, two factors that are fueling market expansion.

Key Players

MRFR recognizes the following companies as the key players in the global Benign Prostatic Hyperplasia Treatment market— Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Limited

Segment Analysis

The global benign prostatic hyperplasia treatment market has been segmented based therapeutic class and therapy.

On the basis of therapeutic class, the market is segmented into alpha blockers, 5- alpha reductase inhibitors, phosphodiesterase-5 inhibitors, others. Alpha-blockers segment dominated the global market in 2022. Alpha-blockers cause the muscles in the prostate and bladder neck to relax, which makes it simpler for pee to flow.

Based on therapy, the global benign prostatic hyperplasia treatment market has been segmented into mono drug therapy and combination drug therapy. Mono drug therapy segment dominated the global benign prostatic hyperplasia treatment market in 2022. This is related to the rising demand for alpha-blockers, which help to treat the condition by relaxing the muscles in the prostate and bladder neck and allowing urine to flow more easily.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Benign Prostatic Hyperplasia Treatment Market Research Report

Regional Analysis

The global benign prostatic hyperplasia treatment market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Benign Prostatic Hyperplasia Treatment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Benign Prostatic Hyperplasia Treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Benign Prostatic Hyperplasia Treatment market comprises of Middle East, Africa, and Latin America.

The North America Benign Prostatic Hyperplasia Treatment Market dominated this market in 2022 (45.80%). This is due to the high prevalence of BPH and other lower urinary tract symptoms that go along with it. For instance, according to information from the National Institute of Health, the prevalence of benign prostatic hyperplasia can reach 50% to 60% in guys in their 60s and rise to 80% to 90% in those over 70.

Moreover, in 2022, the Benign Prostatic Hyperplasia Treatment market in Europe held a sizable market share. This is brought on by a rise in the prevalence of BPH, unhealthy lifestyles that lead to obesity, the presence of notable people, and increased healthcare costs in the region.

Additionally, from 2023 to 2032, the Asia Pacific Benign Prostatic Hyperplasia Treatment market is anticipated to develop significantly. This is caused by an increase in the older population in the area, research and development, epidemics of urological diseases, unmet medical demands, and investments in the healthcare sector.

Furthermore, the rest of the world's Benign Prostatic Hyperplasia Treatment market is divided into the Middle East, Africa, and Latin America. Due to factors like an aging population, rising BPH awareness, and improved healthcare infrastructure, the market for benign prostatic hyperplasia (BPH) treatments is expanding steadily in Latin America. In order to address the rising prevalence of BPH in the area, the market includes medicines, minimally invasive procedures, and surgical therapies.

Key Findings of the Study

• The global benign prostatic hyperplasia treatment market is expected to reach USD 18.1 Billion by 2032, at a CAGR of 5.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. This is caused by an increase in the older population in the area, research and development, epidemics of urological diseases, unmet medical demands, and investments in the healthcare sector.


• Based on therapy, the mono drug therapy segment was attributed to holding the largest market in 2022.


• Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Limited